In late 2011, a new method of fetal genetic testing was introduced. Called cell-free fetal DNA testing or non-invasive prenatal testing (NIPT), this testing uses maternal blood to test for abnormalities in the fetal DNA. First introduced to detect Down syndrome (trisomy 21), the test is now also used to detect the less common trisomies 18 and 13 as well as other conditions. This type of test is offered by several different companies that each have their own brand name for the test.
We offer NIPT to all women at increased risks for the designated conditions. Those in the high-risk group include women over the age of 35, someone with a blood test result or ultrasound marker associated with a chromosome abnormality, and anyone with a family history or previous pregnancy with a history of one of these conditions.
NOTICE: Except where otherwise noted, all articles are published under a Creative Commons Attribution 3.0 license. You are free to copy, distribute, adapt, transmit, or make commercial use of this work as long as you attribute the University of Michigan Health System as the original creator and include a link to this article.